| Date | Time | Source | Announcement |
|---|---|---|---|
| 21 Sep 2018 | 11:24 AM | Result of AGM | |
| 28 Aug 2018 | 07:00 AM | Posting of Annual Report and Notice of AGM | |
| 16 Aug 2018 | 07:00 AM | Final Results | |
| 13 Aug 2018 | 07:00 AM | Trading Update | |
| 20 Jun 2018 | 01:06 PM | Ongoing discussions with MAB Discovery | |
| 24 May 2018 | 07:00 AM | Receipt of additional grants from Invest NI | |
| 09 May 2018 | 03:40 PM | Holding(s) in Company | |
| 23 Apr 2018 | 10:09 AM | Investor presentation | |
| 05 Mar 2018 | 07:00 AM | Trading Statement | |
| 01 Mar 2018 | 07:00 AM | Receipt of grants from Invest Northern Ireland | |
| 16 Jan 2018 | 10:06 AM | Director dealing | |
| 21 Dec 2017 | 09:35 AM | Holding(s) in Company | |
| 21 Dec 2017 | 09:33 AM | Holding(s) in Company | |
| 19 Dec 2017 | 07:00 AM | Holding(s) in Company | |
| 19 Dec 2017 | 07:00 AM | Holding(s) in Company | |
| 18 Dec 2017 | 08:00 AM | Admission to AIM and first day of dealings |
Fusion Antibodies is a biotechnology company that specializes in antibody development services for the healthcare industry. The company was founded in 2001 as a spin-out from Queen's University Belfast and is headquartered in Belfast, Northern Ireland. Fusion Antibodies offers antibody discovery, engineering, supply, and cell line development. It has developed proprietary technology platforms such as CDRx® for antibody humanization, RAMP® for affinity maturation, and ADD™ for developability optimization.
FAB share price launched at 165p in 2017.